For TAMs, targeting the folate receptor β (FRβ) with a CAR in syngeneic mouse models was shown to be safe and promoted increased infiltration of MSLN CAR-T cells in multiple tumor models (114). This evidence concerns the gene FOLR2 and neoplasm.